| scholarly article | Q13442814 |
| P2093 | author name string | Li H | |
| Liu L | |||
| Zhu B | |||
| Thompson WJ | |||
| Fetter J | |||
| Pamukcu R | |||
| Piazza GA | |||
| Ahnen D | |||
| Sperl G | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| P304 | page(s) | 3338-3342 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin | |
| P478 | volume | 60 |
| Q89538287 | 4E-BP1Thr46 Phosphorylation Association with Poor Prognosis in Quantitative Phosphoproteomics of Portal Vein Tumor Thrombus Revealed that 4E-BP1Thr46 Phosphorylation is Associated with Poor Prognosis in HCC |
| Q33390197 | A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state |
| Q35582287 | A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. |
| Q36537864 | A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity |
| Q34525861 | A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone |
| Q36854046 | Activation of the Wnt signaling pathway in chronic lymphocytic leukemia |
| Q39552261 | Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on hum |
| Q34808083 | Bacterial enterotoxins are associated with resistance to colon cancer. |
| Q40286688 | Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. |
| Q44445074 | Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. |
| Q38123175 | COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs |
| Q42176198 | Ca2+/calmodulin‐stimulated PDE1 regulates the beta‐catenin/TCF signaling through PP2A B56 gamma subunit in proliferating vascular smooth muscle cells |
| Q39199574 | Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells |
| Q27023845 | Chemoprevention in familial adenomatous polyposis |
| Q35859243 | Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention |
| Q42135630 | Colon Tumor Cell Growth–Inhibitory Activity of Sulindac Sulfide and Other Nonsteroidal Anti-Inflammatory Drugs Is Associated with Phosphodiesterase 5 Inhibition |
| Q42277641 | Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy |
| Q48550061 | Cyclic-GMP-Elevating Agents Suppress Polyposis in ApcMin mice by Targeting the Preneoplastic Epithelium |
| Q36602684 | Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. |
| Q28168895 | Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells |
| Q26829126 | Emerging role of the β-catenin-PPARγ axis in the pathogenesis of colorectal cancer |
| Q54301069 | Expression of cGMP-dependent protein kinase, PKGIα, PKGIβ, and PKGII in malignant and benign breast tumors. |
| Q28254667 | GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease |
| Q36830763 | GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases |
| Q36526265 | Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. |
| Q38900900 | H89 enhances the sensitivity of cancer cells to glyceryl trinitrate through a purinergic receptor-dependent pathway |
| Q36202841 | Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. |
| Q38802590 | Inducible Nitric Oxide Synthase in the Carcinogenesis of Gastrointestinal Cancers |
| Q28193048 | Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells |
| Q35151018 | Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells |
| Q40579631 | Inhibition of human glioma cell growth by a PHS-2 inhibitor, NS398, and a prostaglandin E receptor subtype EP1-selective antagonist, SC51089. |
| Q35449858 | Involvement of VILIP-1 (visinin-like protein) and opposite roles of cyclic AMP and GMP signaling in in vitro cell migration of murine skin squamous cell carcinoma |
| Q33352757 | Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480. |
| Q38169133 | NSAIDs inhibit tumorigenesis, but how? |
| Q38974324 | NSAIDs: Old Drugs Reveal New Anticancer Targets. |
| Q42775840 | National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms |
| Q38034670 | New NSAID targets and derivatives for colorectal cancer chemoprevention. |
| Q53249505 | New approaches to the treatment of advanced prostate cancer. |
| Q36808335 | Nexavar/Stivarga and viagra interact to kill tumor cells |
| Q38837269 | Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression |
| Q36637814 | Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases |
| Q36808317 | OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies |
| Q55457391 | Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas. |
| Q35827798 | PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer |
| Q39721627 | PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4. |
| Q37395863 | Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells |
| Q46078166 | Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis |
| Q36924607 | Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study |
| Q42378330 | Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling |
| Q34416260 | Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity |
| Q36503940 | Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment |
| Q47171803 | Phosphodiesterase type 5 and cancers: progress and challenges |
| Q36215141 | Phosphodiesterases in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia |
| Q47138288 | Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer |
| Q35597651 | Prevention and management of duodenal polyps in familial adenomatous polyposis |
| Q39922850 | Receptor guanylyl cyclase C (GC-C): regulation and signal transduction |
| Q34289307 | Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs |
| Q34234828 | Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs |
| Q55247585 | Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents. |
| Q36952021 | Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants |
| Q34241272 | Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells |
| Q84159289 | Sex modulates intestinal transformation by the tumor-suppressor GCC |
| Q35108211 | Sex modulates intestinal transformation by the tumor-suppressor GCC. |
| Q36782452 | Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95 |
| Q53187152 | Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice. |
| Q36420145 | Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo |
| Q38724210 | Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells |
| Q35760255 | Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study |
| Q35020902 | Stabilization of cGMP-dependent protein kinase G (PKG) expression in vascular smooth muscle cells: contribution of 3'UTR of its mRNA |
| Q24794243 | Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients |
| Q37238527 | Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling |
| Q28479206 | Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα |
| Q33585342 | Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G |
| Q28166679 | Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines |
| Q36413785 | Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. |
| Q37167091 | Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective. |
| Q35142855 | Targeted therapy for lung cancer |
| Q91928988 | Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs |
| Q58798789 | The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia |
| Q36458158 | The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma |
| Q33768672 | The interaction between the Wnt/β-catenin signaling cascade and PKG activation in cancer |
| Q37693485 | The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment |
| Q33748280 | Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma |
| Q47104845 | Validation of PDE5 as a Chemoprevention Target |
| Q34765533 | cGMP-dependent protein kinase Iβ interacts with p44/WDR77 to regulate androgen receptor-driven gene expression |
| Q34244951 | cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action |
Search more.